Lesley Attkisson Lewis Receives The M&A Advisor’s 14th Annual Emerging Leaders Award
Moore & Van Allen PLLC (MVA) is pleased to announce that Corporate Member Lesley Attkisson Lewis has been selected as a winner of The M&A Advisor’s 14th Annual Emerging Leaders Awards. Lewis was chosen from a pool of prominent nominees based on her notable accomplishments in business and service to the community.
The M&A Advisor established the Emerging Leaders Awards program to promote mentorship and professional development among the emerging leaders of corporate finance and dealmaking industries. Evaluation and selection of the nominees was completed by an independent judging panel. The 2023 recipients will be formally honored at an awards gala in New York City this September.
“With the challenges undertaken over the past three years, especially with the pandemic and with challenging economic uncertainty, our selected honorees are at the top of their game,” said The M&A Advisor Founder and CEO Roger Aguinaldo. “The 2023 award recipients join a truly remarkable, global network of outstanding young professionals.”
In her practice, Lewis handles a broad range of corporate transactional matters, with a focus on mergers, acquisitions, divestitures, carve-out transactions, and private equity investments. She also routinely advises clients in general corporate matters, such as the formation, structuring, and governance of privately held business entities, and the drafting and negotiating of commercial contracts. Her clients hail from across many industries, including manufacturing, software, packaging, transportation and logistics, life sciences, and energy.
In addition to her demanding practice, Lewis is an involved member of MVA’s noted Public Service Committee, through which she serves as long-time coordinator of the Devonshire Elementary School Reading Program. She has also served on the Juvenile Diabetes Research Foundation’s (JDRF) Hope Gala Committee since 2019. The annual gala is JDRF Charlotte’s biggest fundraising event every year, with proceeds going directly toward type 1 diabetes (T1D) research.